Canada’s national pharmacare program is currently at a standstill, as the federal government is not engaging in discussions with the remaining provinces and territories to finalize agreements. The recent budget did not allocate additional funding for expanding coverage nationwide, raising concerns about the future of the public drug plan.
Over a year ago, the Canada Pharmacare Act was passed by the Trudeau Liberals, outlining the commitment to partnering with all provinces and territories to cover the costs of contraceptive and diabetes medications and devices. While four provinces and territories – B.C., Manitoba, P.E.I., and Yukon – signed agreements with Ottawa before the federal election, no new deals have been announced since then.
Health Minister Marjorie Michel stated that her department is not actively negotiating with other provinces at the moment, despite ongoing conversations about future steps. Some provinces, such as Ontario, Saskatchewan, and New Brunswick, have expressed readiness to engage with Ottawa. However, Alberta has raised concerns about the program’s long-term sustainability and the need for autonomy in determining covered medications.
Although some provinces are eager to sign agreements under the initial framework, others, like Nova Scotia, have yet to receive responses from the federal government after expressing interest in restarting discussions. The lack of new funding in the latest budget has led to skepticism among pharmacare advocates, who point out that the existing agreements only cover 17% of Canadians, highlighting disparities in access to essential medications.
The federal government’s messaging on pharmacare has been inconsistent, with Prime Minister Mark Carney previously committing to signing remaining agreements while acknowledging the financial challenges. The absence of additional funding in the budget has raised doubts about the government’s dedication to expanding pharmacare nationwide, prompting concerns about the program’s future and accessibility for all Canadians.